Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Student-built exoskeleton mimics human knee

Mechanical engineers from ETH Zurich (Swiss Federal institute of Technology) are developing a new powered exoskeleton that they hope will improve the lives of paraplegics by allowing them to walk with greater freedom than possible with current assisted walking devices. Metal exoskeleton suits worn outside the body, delivering energy for limb movement, are becoming more […]

Read More »

ContextMedia:Health Announces Newest Initiative for Rx Partners: The New Patient Start Program

New service offers partner brands a no-risk approach to drive the marketing outcomes that matter most: new patient starts.

Read More »

Shire Wins Patent Trial Against Watson Concerning LIALDA

The patent for the ulcerative colitis drug LIALDA was upheld and extends through June 8, 2020.

Read More »

Keryx says anemia drug succeeds in study of kidney patients

Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.

Read More »

Sanofi Poaches Top AstraZeneca PLC Scientist

March 29, 2016By Mark Terry, Breaking News Staff   Paris-based Sanofi (SNY) announced today that it had appointed Yong-Jun Liu as Head of Research, Global Research and Development starting April 1. He will report to the company’s president of Global Research and Development, Elias Zerhouni. Formerly the head of research at AstraZeneca (AZN)’s MedImmune […]

Read More »

SoCal Biotech TrovaGene’s Stock Tanks After Firing CEO, CFO

March 29, 2016By Mark Terry, Breaking News Staff   San Diego, Calif.-based TrovaGene (TROV) announced yesterday that it had fired the company’s chief executive officer and chief financial officer for cause. The company also filed a lawsuit against both men, Antonius Schuh and Stephen Zaniboni, chief executive officer and chief financial officer, respectively. The […]

Read More »

Biosimilar drugs could save up to $110 billion by 2020: IMS

Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe’s five top markets as much as 98 billion euros ($110 bln) by 2020, a new analysis showed on Tuesday. Realizing those savings, however, depends on effective doctor education and healthcare providers adopting smart market access strategies, the report by […]

Read More »

U.S. lawmakers want health agencies to lower prostate cancer drug cost

The patient’s entrance at the National Institutes of Health is shown in Bethesda, Maryland October 16, 2014. Reuters/Gary Cameron <span class="articleLocation”>A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc’s and Astellas Pharma Inc’s prostate cancer […]

Read More »

Alder drug to prevent migraines successful in mid-stage study

Alder BioPharmaceuticals Inc. said its injection to prevent migraines had met the main goal in a mid-stage study.

Read More »

A Peek into Pfizer’s R&D Process: from Molecule to Medicine

There’s a slightly hollow feeling about the faded business park which was once home to Pfizer’s bustling R&D community and supported thousands of jobs in the nearby town of Sandwich.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom